46 completed. 46 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 46 | Completed 46 |
| Phase 1 | 11 | Completed 11 |
Follow Leukemia, Hairy Cell: new trials by email Literature Review of Leukemia, Hairy Cell trials Research Report on Leukemia, Hairy Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Dabrafenib, Trametinib - Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 206 | 2014-03-12 | 2023-08-21 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Vemurafenib - Hairy Cell Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 36 | 2012-10-01 | 2025-10-20 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Fludarabine, Busulfan, Total Body Irradiation (TBI) - Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2011-08-04 | 2026-04-15 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 63 | 2009-02-01 | 2018-01-02 |
| Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer donor natural killer cell infusion - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 1 / Phase 2 | Completed | Asan Medical Center | 47 | 2009-01-01 | 2013-02-20 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant ondansetron, survey administration, management of therapy complications - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 49 | 2008-08-08 | 2017-05-23 |
| Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy darbepoetin alfa, epoetin alfa, fatigue assessment and management - Anemia, Leukemia | Phase 2 | Completed | Mayo Clinic | 239 | 2007-05-01 | 2017-02-10 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer therapeutic immune globulin, busulfan, fludarabine phosphate - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | Institut Paoli-Calmettes | 82 | 2007-03-01 | 2011-05-17 |
| LMB-2 to Treat Hairy Cell Leukemia Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin - Hairy Cell Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2006-05-02 | 2023-11-14 |
| Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant methotrexate, methylprednisolone, prednisone - Cancer | Phase 2 | Completed | Fred Hutchinson Cancer Center | 53 | 2006-05-01 | 2010-09-14 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis tanespimycin - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 37 | 2006-05-01 | 2012-03-15 |
Showing 20 of 46. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (38) · Lymphoma, B-Cell, Marginal Zone (36) · Lymphoma, Follicular (36) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Hodgkin Disease (35) · Lymphoma, Mantle-Cell (35) · Burkitt Lymphoma (34) · Lymphoma, Non-Hodgkin (34) · Lymphoma, Large B-Cell, Diffuse (33) · Lymphoma, Large-Cell, Immunoblastic (33) · Multiple Myeloma (32) · Lymphoma, T-Cell, Cutaneous (30) · Leukemia, Myeloid, Acute (28) · Mycosis Fungoides (27)
Hematologic Diseases (46) · Hemic and Lymphatic Diseases (46) · Immune System Diseases (46) · Immunoproliferative Disorders (46) · Lymphatic Diseases (46) · Neoplasms by Histologic Type (46) · Lymphoproliferative Disorders (43) · Neoplasms (42) · Chronic Disease (38) · Disease Attributes (38) · Leukemia, B-Cell (38) · Leukemia, Lymphoid (38) · Lymphoma, B-Cell (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38)
Peripheral Blood Stem Cell Transplantation (10) · Mycophenolic Acid (9) · Tacrolimus (9) · fludarabine phosphate (8) · Whole-Body Irradiation (7) · Cyclosporine (5) · Methotrexate (5) · Rituximab (5) · Alemtuzumab (3) · Busulfan (3) · Cyclophosphamide (3) · Therapeutics (3) · merphos (3) · Beclomethasone (2) · Epoetin Alfa (2)
Fred Hutchinson Cancer Center (15) · National Cancer Institute (NCI) (5) · Cancer Treatment Centers of America (2) · National Institutes of Health Clinical Center (CC) (2) · Acerta Pharma BV (1) · Alexey Danilov, MD (1) · Asan Medical Center (1) · Case Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hoag Memorial Hospital Presbyterian (1) · Institut Paoli-Calmettes (1) · Jonsson Comprehensive Cancer Center (1) · Jurgen Barth (1) · Mayo Clinic (1) · MedImmune LLC (1)
United States (41) · Italy (7) · Germany (4) · France (3) · Belgium (2) · Canada (2) · South Korea (2) · Switzerland (2) · Austria (1) · Denmark (1) · Japan (1) · Netherlands (1) · Norway (1) · Puerto Rico (1) · Slovakia (1)
Brenda Sandmaier (3) · David Maloney (3) · Alan Saven, MD (1) · Albert von Rohr, MD (1) · Anastasios Raptis, MD (1) · Ann Traynor, MD (1) · Antonio T. Fojo, MD, PhD (1) · Charles L. Loprinzi, M.D. (1) · Claudio Anasetti, MD (1) · Claudio Viscoli, MD (1) · Craig Okada, M.D. (1) · David Hockenbery, MD (1) · Didier Blaise, MD (1) · Elizabeth C. Dees, MD (1)
PMID 32499241, PMID 18596230, PMID 18327587, PMID 18603561, PMID 18989154, PMID 19170225, PMID 19841031, PMID 19900571, PMID 25092772, PMID 26213141, PMID 26352686, PMID 28314788, PMID 29072975, PMID 31481800, PMID 32818466, PMID 34196037, PMID 34838156, PMID 35930750, PMID 36108341, PMID 37059834, PMID 37219859, PMID 37934000, PMID 42308249
P30CA015704 (6), P01CA018029 (3), P01CA078902 (3), N01CM00039 (1), N01CM62202 (1), P30CA008748 (1), P30CA015083 (1), P30CA016672 (1), P30CA036727 (1), P30CA043703 (1), P30CA046592 (1), U01CA069856 (1), U10CA081920 (1)